Diagnostic value of UroVysion FISH for detecting urological malignancy and its use in monitoring recurrence of bladder cancer

doi:10.16150/j.1671-2870.2018.02.008

Abstract

Abstract: Objective: To assess the value of UroVysion FISH for screening urological malignancy and to explore its potential application in monitoring of recurrence of bladder cancer. Methods: Fresh urine specimens were collected from 368 cases with hematuria and/or history of urological cancer during follow-up. Diagnostic performance of UroVysion FISH for screening urological malignancy was evaluated in accordance with the results of pathology. Further analysis especially in patients with hematuria was conducted to determine the value of UroVysion FISH for detecting urological malignancy as well as for monitoring recurrence of bladder cancer. Results: ① The sensitivity of UroVysion FISH for detecting urological malignancy (bladder cancer, renal cancer, carcinoma of ureter, prostatic cancer) in patients with hematuria was superior to that without hematuria(P<0.005). ② Results of UroVysion Fish were closely related to tumor grade of urological malignancy. The sensitivity and specificity of UroVysion Fish for diagnosing high-stage tumor were higher than those of low-stage, especially in patients with hematuria. ③ A total of 45.51%(71/156) patients who eventually diagnosed as bladder cancer had cancer recurrence, and 57.75%(41/71) of them could be predicted according to the results of UroVysion Fish. ④ Results of FISH for bladder cancer follow-up in patients with hematuria showed higher sensitivity than in patients with history of urological malignancy. Conclusions: UroVysion FISH has high sensitivity and specificity for detecting urological malignancy, and the results are strongly relevant to tumor malignancy and invasion. UroVysion FISH is valuable for monitoring recurrence of bladder cancer, especially in patients with hematuria.

Key words: Fluorescence in situ hybridization, Urological malignancy, Bladder cancer, Hematuria, Prognosis

CLC Number:

R737.1

XU Ling, WANG Genfa, ZHANG Liang. Diagnostic value of UroVysion FISH for detecting urological malignancy and its use in monitoring recurrence of bladder cancer[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(02): 159-164.

References

[1] Griffiths TR, Action on Bladder Cancer. Current perspectives in bladder cancer management[J]. Int J Clin Pract,2013,67(5):435-448.
[2] Crawford JM.The origins of bladder cancer[J]. Lab Invest,2008,88(7):686-693.
[3] Grossman HB, Gomella L, Fradet Y, et al.A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer[J]. J Urol,2007,178(1):62-67.
[4] Sullivan PS, Nooraie F, Sanchez H, et al.Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study[J]. Cancer,2009,117(3):167-173.
[5] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2016[J]. CA Cancer J Clin,2016,66(1):7-30.
[6] Fadl-Elmula I, Gorunova L, Mandahl N, et al.Cytogene-tic analysis of upper urinary tract transitional cell carcinomas[J]. Cancer Genet Cytogenet,1999 ,115(2):123-127.
[7] Caraway NP, Khanna A, Fernandez RL, et al.Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study[J]. Cancer Cytopathol,2010,118(5):259-268.
[8] Hajdinjak T.UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing[J]. Urol Oncol,2008, 26(6):646-651.
[9] Dimashkieh H, Wolff DJ, Smith TM, et al.Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation[J]. Cancer Cytopathol,2013,121(10):591-597.
[10] Schmitz-Dräger BJ, Droller M, Lokeshwar VB, et al.Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus[J]. Urol Int,2015,94(1):1-24.
[11] Karaoglu I, van der Heijden AG, Witjes JA. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer[J]. World J Urol, 2013,32(3):651-659.
[12] Black PC, Brown GA, Dinney CP.Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer[J]. J Clin Oncol,2006,24(35): 5528-5535.
[13] Gudjónsson S, Isfoss BL, Hansson K, et al.The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer[J]. Eur Urol,2008,54(2):402-408.
[14] Ather MH, Nazim SM.New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer[J]. Korean J Urol,2015,56(8):553-564.

[1]	XIE Wen, LIANG Huaiyu, DONG Lei, YUAN Fei, WANG Chaofu, GUO Yan. Analysis of genetic status of pivotal driver genes in pancreatic ductal adenocarcinoma and their correlation with clinicopathologic features [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 581-587.
[2]	LI Lei, YUAN Fei, WANG Chaofu, XU Haimin, WANG Ting. Ampullary adenocarcinoma: analysis of the clinicopathological features and prognostic factors [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 355-361.
[3]	FENG Guowei, ZHANG Xiaojuan, GUO Rui, GUAN Zhe, WANG Yue. The prognostic value of pretreatment ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 533-539.
[4]	LIANG Yali, ZHAO Haigang, XIANG Guangyu. The stress-induced hyperglycemia ratio in the prognosis prediction of patients with acute ischemic stroke one year after thrombolytic therapy [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 562-566.
[5]	FENG Mingyang, DING Yezhou, ZHAO Qingqing, ZHAO Gangde, LOU Shike, ZHENG Chao, SUN Xuehua, LIU Kehui, LIN Lanyi, XIE Qing, ZHENG Lan, WANG HUI. Relation of TCM syndrome type in traditional Chinese medicine with liver failure staging in Western medicine in patients with liver failure [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(04): 391-395.
[6]	RUI Wenbin, XU Da, ZHU Yu, WU Yuxuan, WANG Haofei, WANG Chenghe, YUAN Fei. Expression of HIF-1α and its relationship with prognosis in papillary renal cell carcinoma [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(03): 265-370.
[7]	ZHANG Zhongwen, ZUO Xiangrong, ZHENG Xuhui, CAO Quan, Li Xinli, LI Yanxiu. Correlation between gene polymorphism of chromosome 3q26 rs12696304 and 1-year survival rate after acute heart failure in an elderly Han population in South China [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(06): 565-571.
[8]	DU Hailei, CHEN Ling, LUO Fangxiu, LI Yong, CHENG Qijian, ZHU Lianggang, HANG Junbiao. The prognostic value of Beclin-1 and Bcl-2 and its relationship with pathological characteristics in patients with non-small cell lung cancer [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 258-263.
[9]	XU Zhaoping, WANG Haofei. Expression of ZNF692 gene in clear cell renal cell carcinoma and its relationship with prognosis [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 292-296.
[10]	LUO Xiaoying, ZHU Xuemei, XU Yan, ZHANG Fengru, WU Liqun, QI Wenhang. Value of NT-proBNP level in predicting prognosis of hospitalized elderly pneumonia patients without heart failure history [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(03): 319-322.
[11]	SONG Dandan, CHANG Chunkang, GUO Juan, XU Feng, ZHAO Youshan, WU Lingyun. The abnormal percentage of bone marrow macrophages and its clinical significances in myelodysplastic syndromes [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 439-443.
[12]	JI Haifeng, YANG Xuelian, YAO Yulan, CAI Liying, LAI Xiaoyin, WU Dayu, XU Yumei, JIANG Mei. Validation of mSORE score for predicting poor outcome in acute ischemic stroke [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 423-427.
[13]	YAO Yulan, GUO Enwei, REN Dali, ZHANG Bingyu, YANG Feng, CHEN Qing, LIU Xinghui, LUO Qiancheng, FENG Gang. Correlation of serum interleukin 33 and soluble suppression of tumorigenicity 2 with injury severity and prognosis in trauma patients [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 299-303.
[14]	WANG Ting, XIE Wen, LIN Xiaozhu, YUAN Fei, WANG Chaofu, GUO Yan. Intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas: analysis of the clinicopathologic features and prognosis [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 278-284.
[15]	DU Hailei, CHE Jiaming, ZHU Lianggang, LI Hecheng, HANG Junbiao. Clinical characteristics of different pathological subtypes of T₁ invasive lung adenocarcinoma and analysis of prognosis [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 82-86.